Recent Updates
Recently added Catalysts

DFD06

Phase 3

Psoriasis | Small molecule | Immunology |Dr. Reddy's Laboratories Ltd|Last Updated: May 18, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment317
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02635204A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque PsoriasisPHASE3 COMPLETED 267Dec 1, 2015Jul 1, 2016May 15, 201830 United States
NCT02131324DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque PsoriasisPHASE2 COMPLETED 50May 8, 2014Aug 11, 2016May 18, 201815 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Subjects With Treatment Success at Day 15
Day 15 Visit

The percentage of subjects with treatment success (defined as IGA = 0 or 1 and at least a 2-grade reduction from baseline) at the Day 15 visit. Primary analysis was done with multiple imputations. Results are combined analyses from 5 imputed data sets.

The Percentage of Subjects With HPA Axis Suppression.
Day 15

HPA axis suppression as measured by serum cortisol levels post cosyntropin test (ACTH test)

Secondary Endpoints
Percent Change From Baseline in Body Surface Area at Day 15
Baseline and Day 15
Percent of Subjects With Treatment Success at Day 8 Visit
Baseline and Day 8
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
DFD-06 CreamEXPERIMENTALDFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
Vehicle CreamPLACEBO_COMPARATORVehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
Clobetasol Propionate Cream, 0.05%ACTIVE_COMPARATORapplied twice a day for 15 days
DFD06 CreamEXPERIMENTALapplied twice a day for 15 days
Interventions
NameTypeDescription
DFD06 CreamDRUGTwice daily topical application for 14 days.
Vehicle CreamDRUGTwice daily topical application for 14 days.
Clobetasol Propionate Cream 0.05%DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites30

Inclusion Criteria: 1. Subject understands the study procedures and agrees to participate by giving written informed consent. Subjects must be willing to authorize use and disclosure of protected health information collected for the study. 2. Subject must be at least 18 years of age. 3. Subject mus...

Countries:United States
Unlock Eligibility Criteria